Exercise Limitations in Heart Failure with Reduced and Preserved Ejection Fraction
Overview
Affiliations
The hallmark symptom of chronic heart failure (HF) is severe exercise intolerance. Impaired perfusive and diffusive O transport are two of the major determinants of reduced physical capacity and lowered maximal O uptake in patients with HF. It has now become evident that this syndrome manifests at least two different phenotypic variations: heart failure with preserved or reduced ejection fraction (HFpEF and HFrEF, respectively). Unlike HFrEF, however, there is currently limited understanding of HFpEF pathophysiology, leading to a lack of effective pharmacological treatments for this subpopulation. This brief review focuses on the disturbances within the O transport pathway resulting in limited exercise capacity in both HFpEF and HFrEF. Evidence from human and animal research reveals HF-induced impairments in both perfusive and diffusive O conductances identifying potential targets for clinical intervention. Specifically, utilization of different experimental approaches in humans (e.g., small vs. large muscle mass exercise) and animals (e.g., intravital microscopy and phosphorescence quenching) has provided important clues to elucidating these pathophysiological mechanisms. Adaptations within the skeletal muscle O delivery-utilization system following established and emerging therapies (e.g., exercise training and inorganic nitrate supplementation, respectively) are discussed. Resolution of the underlying mechanisms of skeletal muscle dysfunction and exercise intolerance is essential for the development and refinement of the most effective treatments for patients with HF.
Triangto I, Dhamayanti A, Putra M, Witjaksono D, Rahmad , Zuhriyah L Ann Rehabil Med. 2025; 49(1):23-29.
PMID: 40033954 PMC: 11895058. DOI: 10.5535/arm.240057.
Huang Q, Yuan Q, Li W, He X, He Q, Deng Z Front Med (Lausanne). 2025; 12:1446782.
PMID: 39917066 PMC: 11801010. DOI: 10.3389/fmed.2025.1446782.
Lopez-Usina A, Mantilla-Cisneros C, Llerena-Velastegui J J Clin Med Res. 2024; 16(10):449-464.
PMID: 39544327 PMC: 11557505. DOI: 10.14740/jocmr6033.
Cipriano Jr G, da Luz Goulart C, Chiappa G, da Silva M, Silva N, do Vale Lira A Sci Rep. 2024; 14(1):22505.
PMID: 39341902 PMC: 11439022. DOI: 10.1038/s41598-024-72965-0.
Santos-de-Araujo A, Bassi-Dibai D, Dourado I, da Luz Goulart C, Marinho R, de Almeida Mantovani J Diabetol Metab Syndr. 2024; 16(1):229.
PMID: 39272115 PMC: 11401430. DOI: 10.1186/s13098-024-01464-z.